The major limitations of viral vectors, particularly those related to safety and immunogenicity, have prompted studies to improve methods of non-viral gene delivery.
The major limitations of viral vectors, particularly those related to safety and immunogenicity, have prompted studies to improve methods of non-viral gene delivery. 1 Among such non-viral vectors, cationic liposomes are one of the more promising non-viral systems for use in gene therapy. 2 The efficient delivery of functional therapeutic genes into target cells is an important problem in gene therapy approaches for the treatment of cancer and metabolic diseases, as well as human immunodeficiency virus infection.
A number of receptor-mediated gene delivery systems have been developed to introduce DNA into specific cell types in vivo. The liver is one of the important target organs for gene delivery, because this organ plays a central role in the metabolism and production of many kinds of enzymes. Asialoglycoprotein receptor ligands investigated for use especially for hepatocytes include galactose residues [3] [4] [5] and asialofetuin. [6] [7] [8] However, synthesis and purification of these ligands are expensive. We reported previously that liposomes containing soybean-derived sterylglucoside (SG) accumulate in the hepatocytes after intravenous injection at almost the same level as liposomes containing lactosylceramide, which is a galactose- terminated compound.
9-11 SG, an abundant plant sterylglucoside, can be inexpensively obtained. We also reported that SG-containing liposomes are potentially useful vectors for transfer of DNA into human hepatoblastoma (HepG2) cells. 12 However, the transfection efficiency in vitro was not so high in medium without serum, and the size of the liposome/DNA complex was too large for efficient use in vivo.
We supposed that the electrostatic interaction of cationic SG-liposomes with DNA was not sufficient to allow the formation of a liposome/DNA complex with small particle size. Therefore, we designed highly positively charged small-sized liposomes that after mixing with water phase containing DNA can become loaded with DNA resulting in formation of a small liposome/DNA complex. For liver targeting, we prepared liposomes containing ␤-sitosterol ␤-d-glucoside (Sit-G), which is the main component of SG (Sit-G-liposomes). To increase the positive charge in the liposomes, we selected Tfx-20 reagent (Tfx) and 3␤[N-(NЈ, NЈ-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) as cationic lipids, because the former is composed of synthetic cationic lipid [N,N,NЈ,NЈ-tetramethyl-N,NЈ-bis(2-hydroxy ethyl)-2,3-di (oleoyloxy)-1,4-butanediammonium iodide] that leads to high transfection efficiency in cell lines 13 and the latter has already been used clinically for gene therapy. 14, 15 To prepare small liposomes, we used the modified ethanol injection method.
In this study, we prepared highly positively charged small Sit-G-liposomes, optimized the ratio of plasmid DNA encoding the luciferase reporter gene to Sit-G-liposomes by evaluating transfection efficiency in HepG2 cells in the presence of serum in the medium, and investigated the gene expression of Sit-G-liposome/DNA complex following intravenous injection into mice.
Sit-G-liposomes (78 ± 2 nm) with a high positivepotential (33.8 ± 7.0 mV), were shown to be round in shape by microscopic observation (data not shown). The Sit-G-liposome suspension was very stable, and could be stored for several months at 4°C without any change in particle size (data not shown). The particle size andpotential of Sit-G-liposome/DNA complexes were dependent on charge ratio (+/−) of cationic lipid to DNA (Figure 1) . At a charge ratio (+/−) of about 3, the largest average particle size and variance of complex (1200 ± 247 nm) were observed when the -potential approached Gene Therapy approximately zero (0.1 ± 0.3 mV). Except at a charge ratio of 3, the particle size of liposome/DNA complex was in the range of about 100-250 nm.
N, N, NЈ, NЈ-tetramethyl-N,NЈ-bis(2-hydroxyethyl)-2,3-di(oleoyloxy)-1,4-butanediammonium iodide] and Ldioleoylphosphatidylethanolamine (DOPE) (weight ratio, 1/3; molar ratio, 1/4). Sit-G (MW 578.84) and DC-Chol were purchased from Essential Sterolin Products (Midrand, South Africa), and Sigma Chemical Co (St Louis, MO, USA), respectively. Sit-G-liposomes were prepared from Tfx (cationic lipid/DOPE = 1/3, weight ratio), DC-Chol and Sit-G (Tfx/DC-
To optimize the ratio of DNA to Sit-G-liposomes, reporter gene expression in HepG2 cells transfected with Sit-G-liposomes at various charge ratios (+/−) in medium with or without serum was investigated (Figure 2 ). The charge ratio (+/−) associated with the highest transfection efficiency of the Sit-G-liposome/DNA complex was shifted from 3 to 4 by addition of 10% serum to the medium. On incubation for 1 h in medium containing serum, particle size of the Sit-G-liposome/DNA complex at a charge ratio (+/−) of 4 increased from 240 ± 16 nm to about 3 m, and -potential decreased from 27.9 ± 5.1 mV to −8.9 ± 2.1 mV. Several serum components such as bovine serum albumin (BSA), heparin, immunoglobulin G and lipoproteins alter the -potential of liposome/DNA complex from positive to negative or neutral. 16, 17 Hence, liposome/DNA complex in medium containing serum might require an excess positive charge, which would result in an increase in the charge ratio (+/−) for high transfection efficiency from 3 to 4.
The efficacy of gene expression in HepG2 cells by Sit-G-liposomes was compared with those of non-Sit-G-lipo- somes at a charge ratio (+/−) of 4 and Tfx (Figure 3 ). According to the manufacturers' protocol (Promega, Madison, WI, USA), the incubation of the Tfx/DNA complex with cells was recommended in serum-free medium for higher transfection efficiency; therefore, we used a charge ratio (+/−) of 2 for use of Tfx from the optimal experiment and performed incubation in medium without serum. Sit-G-liposomes showed significantly higher transfection efficiency than non-Sit-G-liposomes in both the medium with and without serum, but the efficiency was lower than that with Tfx. Both types of liposomes showed significantly increased transfection efficiency in the presence of serum in the medium. This finding suggested that selective gene expression in HepG2 cells was obtained by addition of Sit-G to the liposomes, and was increased by serum. A recent study indicated that SGliposomes are at least partially taken up by asialoglycoprotein receptor-mediated endocytosis. 18 From these findings, it can be estimated that the higher transfection efficiency of Sit-G-liposomes may reflect their increased endocytosis, although as yet we cannot explain the precise details of their mechanism of gene expression. SGliposome showed no serious cytotoxicity in HepG2 cell at the tested concentration (data not shown).
Figure 2 Gene expression in HepG2 cells transfected with Sit-G-liposomes at various charge ratios (+/−) in medium with
Based on their highest transfection efficiency in the presence of serum, we selected liposome/DNA complexes at a charge ratio (+/−) of 4 for in vivo experiments. The biodistributions of gene expression in mice 24 h after intravenous injection with liposome/DNA complexes at a charge ratio (+/−) of 4 and Tfx/DNA at a charge ratio of 2 were examined at a dose of 50 g per mouse ( Figure  4 ). Free DNA (data not shown), Tfx/DNA complex and non-Sit-G-liposome/DNA complex showed very low gene expression in all organs, but Sit-G-liposome/DNA complex showed significantly and selectively higher gene expression in the liver (average 14.9 pg luciferase/mg protein). In the blood stream, disintegration of the Tfx/DNA complex might release associated DNA, which would then be degradated by enzymes, and thus the complex might not act effectively as a gene delivery vector.
For intravenous administration, a small liposome/DNA complex such as Sit-G-liposome/DNA complex is needed, because large liposome complexes are rapidly cleared by the reticuloendothelial system (RES).
Figure 4 Biodistribution of gene expression 24 h after intravenous injec
With regard to dose dependency of gene expression on the amount of DNA in Sit-G-liposome/DNA complexes following intravenous injection into mice, 50 g of DNA showed higher gene expression in the liver than 30 g of DNA, but there was no significant difference between expression at doses of 50 g and 100 g of DNA ( Figure  5 ). Although the levels of gene expression varied between studies, the lungs invariably showed the highest level of expression after intravenous injection of DNA complexed with liposomes without targeting ligands. [19] [20] [21] [22] [23] This is probably because the positively charged larger plasmid DNA/lipid complexes lodge in the pulmonary capillaries, and are captured by RES in the lung. 24 However, in the present study, Sit-G-liposome/DNA complex showed low gene expression in the lung. The small and highly positively charged liposomes containing Sit-G may surround condensed DNA, and form a small liposome/DNA complex. After interaction with blood, the complex coated with serum protein might have a negative -potential and relatively small size, resulting in passage through the lung to the liver.
Sit-G-liposomes appear to be potentially useful vectors for liver targeting showing similar effectiveness to galactosyl ligand, 25 although it is necessary to clarify whether gene expression in the liver is selective for parenchymal or nonparenchymal cells. Twenty-four hours after intravenous injection of non-Sit-G-liposome/DNA complex at a dose of 50 g of DNA, one of five mice died. This might have been due to toxicity caused by aggregates of the complex in serum, as suggested by the observation that non-Sit-G-liposome/DNA complex was larger than Sit-G-liposome/DNA complex in medium containing serum ( Figure 6 ). This finding suggested that addition of Sit-G to liposomes could result in good dispersion of liposome/DNA complex in serum.
In conclusion, we successfully prepared small Sit-Gliposome/DNA complexes with a diameter of approximately 200 nm at pH 7 for liver-targeted gene delivery. The
Sit-G-liposome/DNA complex significantly increased transfection efficiency into HepG2 cells at a Gene Therapy charge ratio (+/−) of 4 with addition of 10% serum to medium, indicating selective gene expression in the liver after intravenous injection into mice, suggesting that the interaction of liposome/DNA complexes with serum may be a key point in predicting the in vivo efficiency of a liposome vector.
Sit-G-liposomes will be useful as vectors for hepatic gene delivery by further improvements such as addition of fusogenic peptide into liposome to increase release of DNA from the complex into the cytosol, and optimization of conditions for complex formation and lipid dose.
